Takeda Pharmaceutical hopes that their $62 billion deal to purchase Shire will make them a global bio-pharmaceutical leader. But as Silvia Antonioli reports, it comes with a heavy debt burden.
TRANSCRIPT +
Takeda Pharmaceutical hopes that their $62 billion deal to purchase Shire will make them a global bio-pharmaceutical leader. But as Silvia Antonioli reports, it comes with a heavy debt burden.